BOSTON -- (EUREKALERT!) -- Alexion Pharmaceuticals, Inc. today announced the first conference presentation of the topline Phase 3 data for ULTOMIRIS ® (ravulizumab), the first and only long-acting C5 ...
- At 26 weeks, 54% of adults and 71% of children treated with ULTOMIRIS demonstrated Complete Thrombotic Microangiopathy (TMA) Response - Atypical HUS affects both adults and children and many ...
Ultomiris is a brand-name biologic medication prescribed for certain rare autoimmune disorders. Dosing of Ultomiris is done via intravenous (IV) infusions administered by a healthcare professional.
– ULTOMIRIS is approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) – PNH is a blood disorder characterized by complement-mediated ...
Dublin, April 13, 2023 (GLOBE NEWSWIRE) -- The "ULTOMIRIS Market Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. The report provides comprehensive ...
Ultomiris (ravulizumab-cwvz) is a prescription drug used to treat certain rare inflammatory conditions. Ultomiris can cause side effects that range from mild to serious. Examples include headache, ...
BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the Phase 3 study of ULTOMIRIS™ (ravulizumab-cwvz), the company’s long-acting C5 complement inhibitor, met its ...
Myasthenia gravis is an autoimmune condition that weakens the muscles in your body. Acetylcholine is a neurotransmitter that helps your muscles move. Most people with generalized myasthenia gravis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results